Tirzepatide, a weekly GLP-1 and GIP drug, produced weight loss of up to 17.8% after 72 weeks. Semaglutide, a weekly GLP-1 ...

The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...

A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s Wegovy, Zepbound maker Eli Lilly said.

Zepbound led to an average weight loss of 20.2 percent compared to ... And of course, pairing the medication with a healthy diet and exercise will help deliver the best results.

Attorney General Kwame Raoul is warning Illinois residents seeking GLP-1 medications – Ozempic, Wegovy, Mounjaro, Zepbound ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.

Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as ... reduce their calorie intake and increase their exercise. Sleep apnea “occurs when a person’s upper ...

The weight loss drug Zepbound has become the first prescription medication ... that the drug is used in combination with a ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...